Ultragenyx Pharmaceutical Inc. (RARE) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -197M | -99.83M | -91.42M | -108.27M | -166.47M | -79.5M | -67M | -76.96M | -190.73M | -83.9M | -117.87M | -116.16M |
| Operating CF Margin % | -144.85% | -48.23% | -57.16% | -65.03% | -119.52% | -48.22% | -48.03% | -52.35% | -175.25% | -65.86% | -120.22% | -107.25% |
| Operating CF Growth % | -18.34% | -25.57% | -36.46% | -40.68% | 12.72% | 5.25% | 43.16% | 33.74% | -21.59% | 7.13% | -23.63% | -50.36% |
| Net Income | -185M | -129M | -180.41M | -114.95M | -151.08M | -133.38M | -133.52M | -131.6M | -170.68M | -123.19M | -159.65M | -159.83M |
| Depreciation & Amortization | -1M | 0 | 8.61M | -11.77M | 8.99M | 9.08M | 8.76M | 8.86M | 8.85M | 8.22M | 7.19M | 5.36M |
| Stock-Based Compensation | 30M | 38M | 37.01M | 38.53M | 39.92M | 40.16M | 41.57M | 39.37M | 36.93M | 33.74M | 34.88M | 34.65M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.26M | 0 |
| Other Non-Cash Items | -41M | -9.42M | -11.48M | 1.73M | -7.67M | -18.11M | -14.63M | -9.96M | -9.79M | -15.98M | -1.83M | -3.51M |
| Working Capital Changes | 0 | 588K | 54.86M | -21.81M | -56.63M | 22.75M | 30.83M | 16.36M | -56.02M | 13.3M | 2.8M | 7.16M |
| Change in Receivables | 19M | -33.83M | 5.42M | -12.65M | 10.06M | -20.64M | 9.79M | 2.16M | -24.91M | 1.01M | -6.2M | -15.08M |
| Change in Inventory | -4M | 150K | -5.59M | 208K | -763K | -2.46M | -2.5M | -4.13M | -2.12M | -1.96M | -3.47M | -1.66M |
| Change in Payables | -57M | 37.01M | 45.12M | -9.68M | -48.45M | 0 | 0 | 25.33M | -35.54M | 0 | 7.48M | 11.78M |
| Cash from Investing | -49M | -72.25M | 117.18M | 71.17M | 119.89M | 102.73M | -275.5M | 60.56M | 94.44M | -107.02M | 64.3M | 99.42M |
| Capital Expenditures | -1M | 0 | -1.28M | -2.46M | -1.32M | -654K | -1.62M | -2.01M | -3.21M | -1.6M | -3.69M | -13.94M |
| CapEx % of Revenue | 0.74% | 0.45% | 0.8% | 1.48% | 0.95% | 0.4% | 1.16% | 1.37% | 2.95% | 1.26% | 3.77% | 12.87% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -5M | -72.25M | 118.46M | -308K | -15.78M | -127K | -203K | -2.54M | -12.06M | -271K | -428K | -2.9M |
| Cash from Financing | 0 | 394.19M | 2K | 83.65M | 157K | 3.19M | 11.17M | 384.94M | -58K | 330.61M | 25.23M | 33.02M |
| Debt Issued (Net) | 0 | 392M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 2.19M | 2K | 83.65M | 0 | 0 | 117K | 0 | 0 | 326.46M | 24.79M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | 157K | 3.19M | 11.06M | 384.94M | -58K | 4.15M | 442K | 33.02M |
| Net Change in Cash | -247M | 221.66M | 26.05M | 49.47M | -44.98M | 23.95M | -330.05M | 367.89M | -97.03M | 140.79M | -29.06M | 16.14M |
| Free Cash Flow | -198M | -100.77M | -92.7M | -95.73M | -182.8M | -80.16M | -68.61M | -81.47M | -203.94M | -85.5M | -121.57M | -132.6M |
| FCF Margin % | -145.59% | -48.68% | -57.96% | -57.5% | -131.23% | -48.62% | -49.19% | -55.41% | -187.39% | -67.12% | -123.98% | -122.43% |
| FCF Growth % | -8.32% | -25.71% | -35.11% | -17.5% | 10.37% | 6.25% | 43.56% | 38.56% | -12.11% | 27.11% | -0.15% | -22.57% |
| FCF per Share | -1.97 | -1.01 | -0.93 | -0.97 | -1.90 | -0.84 | -0.72 | -0.94 | -2.42 | -1.05 | -1.70 | -1.87 |
| FCF Conversion (FCF/Net Income) | 1.06x | 0.77x | 0.51x | 0.94x | 1.10x | 0.60x | 0.50x | 0.58x | 1.12x | 0.68x | 0.74x | 0.73x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |